Subclinical thyroid diseases are defined as an increase or decrease of thyroid-stimulating hormone (TSH) and normal peripheral hormones (thyroxine and triiodothyronine) in serum. The view That patients with long-term untreated subclinical thyroid diseaseshave significant health risks prevails.
The consensus is that subclinical thyroid diseases should be diagnosed and the disease etiology should be defined. Star of treatment is recommended always in cases with TSH below 0.1 mIU/l, unless the cause is extrathyroidal, or over 10.0 mIU/l.
In other cases, the decision on treatment should be individual. Active screening is suitable for population groups at risk.